A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Inclusion Criteria:

• Confirmed diagnosis of mPV by prior or screening biopsy and prior positive anti-DSG3 antibody ELISA

• mPV inadequately managed by at least one standard immunosuppressive therapies

• Active mPV at screening

• Anti-DSG3 antibody ELISA positive at screening

Inclusion Criteria for CABA-201 sub-study

• Confirmed diagnosis of PV by prior or screening biopsy and prior positive DSG3ELISA, IIF, and/or DIF

• PV inadequately managed by at least one standard immunosuppressive therapy

• Active PV at screening

• DSG3 ELISA positive at screening

Exclusion Criteria:

• Active cutaneous lesions associated with PV that indicates mucocutaneous rather thanmucosal-dominant disease

• Rituximab in last 12 months unless PV symptoms have recently worsened or anti-DSG3antibody titers have recently increased

• Prednisone > 0.25mg/kg/day

• Other autoimmune disorder requiring immunosuppressive therapies

• Investigational treatment in last 3 months

Exclusion Criteria for CABA-201 sub-study

• Have paraneoplastic pemphigus or active malignancy (not including non-melanoma skincancer)

• Have received rituximab or other anti-CD20 or anti-CD19 therapies in last 12 monthsunless anti-DSG3 antibody titers have recently increased or PV symptoms haverecently worsened

• Prednisone > 0.25mg/kg/day

• Other autoimmune disorder requiring immunosuppressive therapies

• Investigational treatment in last 3 months